Background: Group 2 innate lymphoid cells (ILC2s) were closely associated with
responses. [6] [7] [8] ILC2s produced dramatic amounts of IL-5, IL-13, some IL-4 and IL-9 in response to the Th2 cell-stimulating cytokines IL-25, IL-33 and thymic stromal lymphopoietin (TSLP) produced by epithelial cells. [9] [10] [11] It was identified that ILC2s mediated airway hyper-reactivity or asthmatic inflammation induced by influenza, 7 protease, 12,13 ryegrass 14 or mite 15 in adaptive immunodeficiency mice. IL-25 and IL-33 mediating airway hyperactivity mostly depended on ILC2s but not the adaptive T cells in mouse. [15] [16] [17] In addition, ILC2s were also found to be increased in several allergic immune diseases in human such as atopic dermatitis, 18, 19 active eosinophilic esophagitis 20 and chronic rhinosinusitis with nasal polyps or eosinophilia. 21, 22 Importantly, high ILC2 levels were found in asthma patients 23 and persistent airway eosinophilia, 24 or rhinovirus-induced asthma exacerbations 25 and AR patients. [26] [27] [28] Only a few studies have reported the effects of medicine treatments on ILC2 levels. ILC2 levels in the lung were decreased after corticosteroid treatment in mouse allergic airway inflammation. 29 Patients with nasal polyps treated with steroids had significantly reduced ILC2s in nasal polyp tissue as compared to those in patients who did not receive steroid treatment. 24 Corticosteroids are the most effective treatment to reduce the airway inflammation and symptoms in asthma and AR patients. 1, 30 The predominant role of ILC2s in asthma pathology indicates the strong possibility of corticosteroid on ILC2 function. Until now only one cross-sectional study has shown that there were high frequencies of IL-13 + ILC2s
in uncontrolled and partly controlled asthma patients than in those in the well-controlled group. 31 Therefore, studies are needed to investigate the effects of corticosteroid therapy on ILC2 levels and their activity in asthma and/or AR patients. Additionally, the signalling pathways involved in the effects of corticosteroid treatment on ILC2s are still unclear.
The aim of this study was to perform a prospective study to evaluate the levels and the function of ILC2s, as well as the relationship with the pulmonary function after glucocorticoid therapy in asthma and asthma with AR patients. In vitro studies were used to investigate the possible signalling pathways involved in the effects of glucocorticoid on ILC2 in allergic airway diseases.
| METHODS
Detailed description of all experimental procedures is provided in the Data S1. experiments in vitro). The inclusion and exclusion criterion are presented in Data S1.
| Study subjects

| Research design and patient treatment
The detailed research design and patient treatment are described in Figure 1 and Data S1. High circulating ILC2s were found in asthma and asthma with allergic rhinitis patients, and significantly decreased after treatment of glucocorticoid.
High levels of IL-5, IL-13 and IL-9 in response to epithelium-derived cytokines were mostly produced by the increased ILC2s from asthma patients. Glucocorticoid treatment is able to reverse the high levels of IL-5 and IL-13 produced by ILC2s via STAT3, STAT5 and STAT6 signalling pathways.
| Peripheral blood collection and flow cytometry analysis for ILC2s
Peripheral blood from the patients was collected for ILC2 examination using flow cytometry. The plasma was used for the determination of IL-13, IL-5 and IL-9.
| ILC2 sorting
Briefly, peripheral blood mononuclear cells (PBMCs) were stained with FITC-Lin + antibodies and FITC-FceR1, and then, the Lin À cells were negatively isolated. The isolated Lin À cells were further stained with PE-CRTH2 and PE-Cy7-CD127 and then sorted into 3 populations.
| The stimulation and treatment of PBMCs,
Lin-cells and ILC2s
A detailed method is provided in Data S1.
| Western blot
Proteins from sorted ILC2s were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membrane was blotted with 10% nonfat milk, probed with the primary antibodies, incubated with secondary antibodies and then visualized by Enhanced Chemiluminescence Plus. 
| Statistical analyses
| RESULTS
| Enhanced ILC2 levels in the patient peripheral blood
The detailed research design and patient treatment are described in Figure 1 . Firstly, we evaluated the ILC2 levels in blood. Human ILC2s
were defined as Lin with that in healthy controls ( Figure 2B ).
There were higher levels of IL-13 in the plasma from asthma patients (P < .001) and asthma with AR patients (P < .01) compared with that from healthy controls ( Figure 2C ). A significant positive correlation was found between the ILC2 percentages and IL-13 levels in asthma patients (P < .05; Figure 2D ) but not in asthma with AR patients ( Figure 2E ) and healthy controls ( Figure 2F ). No IL-5 was detected in the plasma from all subjects. No significant difference for the levels of IL-4 and IL-9 was found between the patients and healthy controls ( Figure S1 ). These findings suggest that ILC2 frequencies were enhanced in both asthma patients and asthma with AR patients.
| Glucocorticoid treatment led to better control in patients
Baseline characteristics of the subjects were listed in Table 1 . The 1-and 3-month follow-ups were completed by 13 and 10 asthma patients, and 15 and 9 asthma with AR patients, respectively ( 
The detailed study design of this study. The patients were evaluated for pulmonary function, FeNO, routine blood test, ILC2 levels and specific IgE at the first visit (0 month), and were treated with glucocorticoid. They were followed up for routine blood test and ILC2 evaluation after 1 month. Three months later, they were evaluated for pulmonary function, FeNO, and routine blood test and ILC2 evaluation again. ACQ-7, seven-item asthma control questionnaire; ACT, asthma control test; AR, allergic rhinitis; FeNO, fractional exhaled nitric oxide; FEV 1 , forced expiratory volume in 1 second [Colour figure can be viewed at wileyonlinelibrary.com]
Test (ACT) values (Table 2) . Taken together, glucocorticoid treatment leads to the better control of asthma and asthma with AR patients.
| Glucocorticoid treatment decreased the ILC2 level and function in asthma and asthma with AR patients
After 1-month glucocorticoid treatment, the ILC2 percentages were significantly decreased in asthma patients (P < .05, n = 13) and asthma with AR patients (P < .01, n = 15) compared with those of the first visit ( Figure S2 , Figure 3A ). The ILC2 percentages were further significantly decreased at 3 months in asthma (n = 10) and asthma with AR patients (n = 9) ( Figure 3A , P < .01 or P < .05). The ILC2 levels in both asthma patients and asthma with AR patients after 3-month treatment were similar to that in healthy controls ( Figure 3B , P > .05).
IL-13 levels in the patient's plasma were also significantly decreased after the treatment (P < .001), and there was a significant difference of IL-13 levels in asthma patients but not asthma with AR patients between 1-or 3-month treatments and 0-month (P < .01, Figure 3C ).
After 3-month treatment, the patients showed the decreased ILC2 frequency but increased FEV 1 and ACT levels. The increased predicted FEV 1 and ACT had relationships with the decreased ILC2 percentages in both asthma and asthma with AR patient groups after the glucocorticoid treatment ( Figure 3D ), which indicates that the patient recovery was accompanied by the decreased ILC2 levels after glucocorticoid treatment. + lymphocytes. ILC2 (B) and IL-13 (C) levels in asthma patients (n = 15), asthma with rhinitis patients (n = 15) and healthy controls (n = 13). IL-13 levels in the plasma were correlated with ILC2 levels in asthma patients (D) but not asthma with AR patients (E) or healthy control (F). *P < .05, **P < .01, ***P < .001. AR, allergic rhinitis YU ET AL.
|
| 1863 percentages with the stimulation or the budesonide treatment using flow cytometry (data not shown). These results suggest that glucocorticoid may mostly affect the ILC2 function but not their frequencies.
Testosterone was reported to negatively regulate ILC2 proliferation and cytokine expression as well as ILC2-mediated allergic airway inflammation. 32 PGE2 suppresses IL-5 and IL-13 production in human tonsillar ILC2s. 33 We examined the effects of testosterone and PGE2 on ILC2 function ( Figure S4 ). Testosterone and PGE2 partly and significantly decreased the levels of IL-5 and IL-13 by PBMCs for patients in response to IL-25/-33/-2 (P < .05). The levels of IL-9 were decreased with the treatment of testosterone and PGE2 in asthma patients (P < .05) but not the other 2 groups. Additionally, the levels of IL-5
and IL-13 were decreased for healthy controls with the treatment of testosterone and PGE2 ( Figure S4 ). It suggests that testosterone and PGE2 have some ability of inhibiting ILC2s to produce of IL-5, IL-13
and IL-9, but weaker than glucocorticoid.
3.5 | ILC2s were predominantly responsible for the robust production of IL-5, IL-13 and IL-9, and glucocorticoid treatment
PBMCs from asthma patients were sorted to 4 subgroups using flow cytometry: ILC2s (Group 1), Lin + PBMCs (Group 2), Lin in Lin + PBMCs (Group 2) ( Figure 5C ). There were also greater IL-13 and IL-9 levels in ILC2 group compared with those in Lin + PBMCs. It suggests that ILC2s were predominantly responsible for the robust production of IL-5, IL-13 and even IL-9. The stimulated high levels of IL-5, IL-13 and IL-9 in the sorted ILC2s from asthma patients were dramatically reversed with the treatment of budesonide ( Figure 5D ).
Using flow cytometry, we found that glucocorticoid receptor (GR) was expressed in ILC2s, and there was no change after the stimulation of epithelial cytokines for 5 days ( Figure S5 ).
| p-STAT3, p-STAT5 and p-STAT6 were involved in the production of IL-5 and IL-13 in ILC2 cells and the effects of glucocorticoid treatment
The Lin À cells which were sorted from the buffy coats from healthy volunteers were used for the evaluation of the phospho- reversed the high IL-5 but not IL-13 levels in ILC2s ( Figure 6C ).
We also investigated the possible upstream signalling pathways.
We found that budesonide significantly inhibited the levels of p-JAK3 ( Figure 6B 
| DISCUSSION
The high frequency and the predominant role of ILC2s in asthma provide a strong hypothesis that therapies for asthma should also consider the ILC2 levels and function. Until now only one study reported that dexamethasone suppresses IL-33-induced airway inflammation and lung natural help cells, a member of ILC2s in mice. 19 For human patients, only one cross-sectional report showed an increased frequency of IL13 + ILC2s in uncontrolled and partly controlled asthma patients when compared to those in the well-controlled group. 31 In our study, we performed a prospective study to evaluate the ILC2 levels and function after glucocorticoid therapy in asthma patients. More importantly, many clinical indicators were evaluated. We found that the glucocorticoid therapy led to ideal control in asthma and asthma with AR patients. More importantly, for both types of patients, the glucocorticoid treatments significantly decreased the blood high frequencies of ILC2s, and ILC2 frequencies at 3 months after the treatment almost reached to normal levels.
Additionally, the improvement of predicted FEV 1 and ACT had Previous study has reported that ILC2s were increased in peripheral blood in asthma patients. 20 Increased ILC2s were found in the blood and sputum in severe asthma patients compared to mild asthma. 23 In our study, all of the patients were newly diagnosed with asthma or asthma with AR, and most of them were not severe.
We identified the enhanced circulating ILC2s in asthma and asthma with AR patients. Previous studies reported higher frequencies of ILC2s in seasonal but not nonseasonal AR patients, 26 and in house dust mite (HDM)-but not mugwort-AR patients. 28 We recently reported that the levels of ILC2s were increased in the HDM-AR patients. 27 In this study, 20% the asthma patients and 100% asthma with AR patients were positive for specific IgE. Our findings have shown that asthma with AR patients had high levels of ILC2s but with no significant difference compared to asthma patients. Recent studies reported that allergen-experienced ILC2s have the activity to acquire memory-like properties, and respond more efficiently during secondary encounters with allergens. 36, 37 Of course, the role of the antigens in the pathology of asthma with or without AR should be further addressed. Additionally, we found that there were higher levels of IL-13 but not IL-4 and IL-9 in plasma in both types of patients, and there was a linear correlation between the ILC2 percentages and the IL-13 levels in asthma patients. All data have provided strong evidence that asthma patients and asthma with AR patients have the increased frequencies of ILC2s and functional cytokine of IL-13 in the circulation.
Previous study has shown that women had increased circulating ILC2 numbers compared to men with moderate-to-severe asthma. 32 Testosterone decreased lung ILC2 numbers and IL-5 and IL-13 expression from ILC2s both in vitro and in vivo. 32 In our study, we did not find significant difference for circulating ILC2 levels in the patients between women and men (data not shown). The inconsistent results may be because of many factors such as the severity of the diseases or different races. PGE2 was reported to suppress IL-5
and IL-13 production in human tonsillar ILC2s. 33 We observed that the treatment of testosterone and PGE2 significantly decreased the high levels of IL-5, IL-13 and IL-9 by the PBMCs from asthma patients in response to epithelial cytokines. However, the effects of both testosterone and PGE2 on the inhibition of Th2 cytokine production were much weaker compared to glucocorticoid.
There were several reports about the signalling pathways involved in ILC2s in asthma. STAT6 deficient will lead to impaired IL-4 and IL-13 receptor expressions as well as proliferation of ILC2s in mouse. 38 Activation of GR inhibits expression of mRNA for STAT5 and JAK3. 39 STAT5 is the key molecule in TSLPinduced corticosteroid resistance in mouse airway inflammation model. 29 IL-7 and TSLP abrogated the inhibition of dexamethasone on type 2 cytokine production by blood ILC2s and induced steroid resistance of ILC2s in a MEK-and STAT5-dependent manner. 30 The steroid resistant of bronchoalveolar lavage fluid (BALF) ILC2s from asthma patients was reversed by inhibitors of MEK and STAT5. 30 In that study, the PBMCs or BALF cells but not sorted We acknowledged the limitation that given the low relative abundance in PBMCs, the relative contribution of ILC2s to the pathogenesis of allergic diseases did not be studied. ILC2s in human bronchoalveolar lavage fluid were not taken into consideration due to the ethical limitation. Further study should be carried out to address glucocorticoid-resistant asthma and ILC2s.
In summary, using a prospective study we identified that increased ILC2s in asthma and asthma with AR patients were inhibited by glucocorticoid treatment. It was confirmed that most IL-5, IL-13 and IL-9 in response to epithelium-derived cytokines were produced by ILC2s. Glucocorticoid treatment was able to reverse the high levels of IL-5, IL-13 and IL-9 produced by ILC2s via STAT3, STAT5, STAT6, JAK3 and MEK signalling pathways. Taken together, our data suggested that glucocorticoid administration could be effective in treating allergic airway inflammation by regulating ILC2s. This will provide a new understanding of glucocorticoid application in regard to allergic diseases.
